Tocilizumab for focal segmental glomerulosclerosis secondary to multicentric Castleman’s disease
- 165 Downloads
Compliance with ethical standards
Full informed consent was obtained from the patient in this report for the treatment. All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
Conflict of interest
Kazuhiro Toyama has the following financial relationship to disclose. Honoraria (lecture fee) from Chugai Pharmaceutical Co., Ltd. (tocilizumab). Masaomi Nangaku has the following financial relationships to disclose. Honoraria (lecture fee) and research funding from Chugai Pharmaceutical Co., Ltd. (tocilizumab). Mineo Kurokawa has the following financial relationship to disclose. Research funding from Chugai Pharmaceutical Co., Ltd. (tocilizumab). The other authors (Drs K.E., Y.M., J.T., H.N., K.H., M.H.) declared that they had no relevant financial relationships to disclose.
- 1.Fajgenbaum DC, Uldrick TS, Bagg A, Frank D, Wu D, Srkalovic G, Simpson D, Liu AY, Menke D, Chandrakasan S, Lechowicz MJ, Wong RS, Pierson S, Paessler M, Rossi JF, Ide M, Ruth J, Croglio M, Suarez A, Krymskaya V, Chadburn A, Colleoni G, Nasta S, Jayanthan R, Nabel CS, Casper C, Dispenzieri A, Fossa A, Kelleher D, Kurzrock R, Voorhees P, Dogan A, Yoshizaki K, van Rhee F, Oksenhendler E, Jaffe ES, Elenitoba-Johnson KS, Lim MS (2017) International, evidence-based consensus diagnostic criteria for HHV-8-negative/idiopathic multicentric Castleman disease. Blood 129(12):1646–1657. https://doi.org/10.1182/blood-2016-10-746933 CrossRefPubMedPubMedCentralGoogle Scholar
- 3.Kawabata H, Kadowaki N, Nishikori M, Kitawaki T, Kondo T, Ishikawa T, Yoshifuji H, Yamakawa N, Imura Y, Mimori T, Matsumura Y, Miyachi Y, Matsubara T, Yanagita M, Haga H, Takaori-Kondo A (2013) Clinical features and treatment of multicentric castleman’s disease : a retrospective study of 21 Japanese patients at a single institute. J Clin Exp Hematop 53(1):69–77CrossRefPubMedGoogle Scholar
- 4.Estrada CC, Paladugu P, Guo Y, Pace J, Revelo MP, Salant DJ, Shankland SJ, D’Agati VD, Mehrotra A, Cardona S, Bialkowska AB, Yang VW, He JC, Mallipattu SK (2018) Kruppel-like factor 4 is a negative regulator of STAT3-induced glomerular epithelial cell proliferation. JCI Insight 3(12). https://doi.org/10.1172/jci.insight.98214
- 5.Savin VJ, Sharma M, Zhou J, Gennochi D, Fields T, Sharma R, McCarthy ET, Srivastava T, Domen J, Tormo A, Gauchat JF (2015) Renal and hematological effects of CLCF-1, a B-cell-stimulating cytokine of the IL-6 family. J Immunol Res 2015:714964. https://doi.org/10.1155/2015/714964 CrossRefPubMedPubMedCentralGoogle Scholar